| 000 | 03188ntm a2200349 i 4500 | ||
|---|---|---|---|
| 003 | MY-KuUP | ||
| 005 | 20260421121423.0 | ||
| 006 | t||||fr|||| 000 0 | ||
| 007 | ta | ||
| 008 | 260421t20252025my a|||fr|||| 000 0 eng d | ||
| 020 |
_aTHE0010485 (Local) _qHardback |
||
| 040 |
_aUMPSA _beng _cUMPSA _erda |
||
| 090 | _aFIST .S54 2025 r Bc. | ||
| 100 | 1 |
_aShanjievan A/l Arivazhagan, _eauthor. |
|
| 245 | 1 | 0 |
_aSynthesis of 2-(3-methoxybenzoyl) cycl ohexan-1-one and exploration of their potential as antialzheimer agents through molecular docking studies / _cShanjievan A/l Arivazhagan |
| 264 | 1 |
_aKuantan, Pahang : _bUMPSA, _c2025 |
|
| 264 | 4 | _c© 2025 | |
| 300 |
_axvii, 77 pages : _billustrations ; |
||
| 336 |
_2rdacontent _atext |
||
| 337 |
_2rdamedia _aunmediated |
||
| 338 |
_2rdacarrier _avolume |
||
| 347 |
_2rda _atext file _bPDF |
||
| 500 | _aFaculty of Industrial Sciences and Technology | ||
| 502 | _aFinal Year Report (Bachelor of Applied Science of Industrial Chemistry) -- Universiti Malaysia Pahang Al-Sultan Abdullah - 2025 | ||
| 504 | _aInclude bibliographical reference | ||
| 520 | 3 | _aAlzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with neuronal death, cognitive decline, and amyloid plaques and neurofibrillary tangles. Treatments available today are limited to symptom management and are often accompanied by significant side effects, highlighting the need for safer and more effective therapeutic agents. In this study, 2-(3-methoxybenzoyl)cyclohexan-1-one was synthesized, characterized using FTIR and NMR, and evaluated for its potential as an anti-Alzheimer agent using molecular docking studies. The compound was made by enamine and acylation reactions, monitored with thin-layer chromatography (TLC), and purified with column chromatography, obtaining 0.3446 g of the product with a 14.9% yield. NMR spectroscopy confirmed 14 distinct carbon environments, and FTIR analysis confirmed diketone peaks at 1710.01 and 1677.84 cm⁻¹, validating the structure of the synthesized compound. Molecular docking studies were performed using SwissDock with the crystal structure of acetylcholinesterase (AChE, PDB ID: 4EY7). The synthesized compound showed a binding affinity of −6.503 kcal/mol, whereas the cocrystallized ligand and FDA-approved drug brexpiprazole displayed binding affinities of −7.261 kcal/mol and −7.962 kcal/mol, respectively. The synthesized compound had a lower binding affinity but exhibited four hydrophobic contacts with ALA397, ALA528, TYR382, and HIS381, and two π-stacking interactions with HIS381 and TYR382 in the AChE active site, suggesting its potential inhibitory activity. The research conducted demonstrates the promise of 2-(3-methoxybenzoyl)cyclohexan-1-one as a candidate AD therapeutic and the utility of combining synthetic chemistry and computational studies to identify and optimize novel therapeutic agents. | |
| 610 | 2 | 0 |
_aFaculty of Industrial Sciences and Technology _xDissertations |
| 650 | 0 |
_aUniversities and colleges _xDissertations |
|
| 650 | 0 |
_aTheses _xDissertations |
|
| 856 | _uhttps://umpir.ump.edu.my/id/eprint/46111 | ||
| 942 |
_2lcc _cPSM |
||
| 999 |
_c104763 _d104769 |
||